These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

771 related articles for article (PubMed ID: 29273067)

  • 41. Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis.
    van der Heijde D; Pangan AL; Schiff MH; Braun J; Borofsky M; Torre J; Davis JC; Wong RL; Kupper H; Collantes E;
    Ann Rheum Dis; 2008 Sep; 67(9):1218-21. PubMed ID: 18056755
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Secukinumab and Sustained Reduction in Fatigue in Patients With Ankylosing Spondylitis: Long-Term Results of Two Phase III Randomized Controlled Trials.
    Kvien TK; Conaghan PG; Gossec L; Strand V; Østergaard M; Poddubnyy D; Williams N; Porter B; Shete A; Gilloteau I; Deodhar A
    Arthritis Care Res (Hoboken); 2022 May; 74(5):759-767. PubMed ID: 33227175
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Efficacy and safety of infliximab plus naproxen versus naproxen alone in patients with early, active axial spondyloarthritis: results from the double-blind, placebo-controlled INFAST study, Part 1.
    Sieper J; Lenaerts J; Wollenhaupt J; Rudwaleit M; Mazurov VI; Myasoutova L; Park S; Song Y; Yao R; Chitkara D; Vastesaeger N;
    Ann Rheum Dis; 2014 Jan; 73(1):101-7. PubMed ID: 23696633
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of secukinumab, a fully human anti-interleukin-17A monoclonal antibody, in patients with moderate-to-severe psoriatic arthritis: a 24-week, randomised, double-blind, placebo-controlled, phase II proof-of-concept trial.
    McInnes IB; Sieper J; Braun J; Emery P; van der Heijde D; Isaacs JD; Dahmen G; Wollenhaupt J; Schulze-Koops H; Kogan J; Ma S; Schumacher MM; Bertolino AP; Hueber W; Tak PP
    Ann Rheum Dis; 2014 Feb; 73(2):349-56. PubMed ID: 23361084
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Comparison of the efficacy and safety of the adalimumab biosimilar TQ-Z2301 and adalimumab for the treatment of Chinese patients with active ankylosing spondylitis: a multi-center, randomized, double-blind, phase III clinical trial.
    Li J; Xue Z; Wu Z; Bi L; Liu H; Wu L; Liu S; Huang X; Wang Y; Zhang Y; Qi W; He L; Dai L; Sun L; Li X; Shuai Z; Zhao Y; Wang Y; Xu J; Zhang H; Yu H; Chen X; Bao C
    Clin Rheumatol; 2022 Oct; 41(10):3005-3016. PubMed ID: 35676450
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial.
    Deodhar A; van der Heijde D; Gensler LS; Kim TH; Maksymowych WP; Østergaard M; Poddubnyy D; Marzo-Ortega H; Bessette L; Tomita T; Leung A; Hojnik M; Gallo G; Li X; Adams D; Carlier H; Sieper J;
    Lancet; 2020 Jan; 395(10217):53-64. PubMed ID: 31813637
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of upadacitinib in patients with ankylosing spondylitis refractory to biologic therapy: 1-year results from the open-label extension of a phase III study.
    Baraliakos X; van der Heijde D; Sieper J; Inman RD; Kameda H; Li Y; Bu X; Shmagel A; Wung P; Song IH; Deodhar A
    Arthritis Res Ther; 2023 Sep; 25(1):172. PubMed ID: 37723577
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of sirukumab in patients with active rheumatoid arthritis refractory to anti-TNF therapy (SIRROUND-T): a randomised, double-blind, placebo-controlled, parallel-group, multinational, phase 3 study.
    Aletaha D; Bingham CO; Tanaka Y; Agarwal P; Kurrasch R; Tak PP; Popik S
    Lancet; 2017 Mar; 389(10075):1206-1217. PubMed ID: 28215362
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Efficacy and Safety of Anti-Interleukin-17A Monoclonal Antibody Secukinumab in Treatment of Ankylosing Spondylitis: A Meta-Analysis.
    Katsevman GA; Mariscal G; Barrios C; Domenech-Fernández P; Ziembinski C; Bhatia S
    Monoclon Antib Immunodiagn Immunother; 2020 Oct; 39(5):160-166. PubMed ID: 33001775
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Pooled safety results across phase 3 randomized trials of intravenous golimumab in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
    Husni ME; Deodhar A; Schwartzman S; Chakravarty SD; Hsia EC; Leu JH; Zhou Y; Lo KH; Kavanaugh A
    Arthritis Res Ther; 2022 Mar; 24(1):73. PubMed ID: 35313978
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial.
    Song IH; Heldmann F; Rudwaleit M; Listing J; Appel H; Braun J; Sieper J
    Arthritis Rheum; 2010 May; 62(5):1290-7. PubMed ID: 20461780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).
    Nash P; Mease PJ; McInnes IB; Rahman P; Ritchlin CT; Blanco R; Dokoupilova E; Andersson M; Kajekar R; Mpofu S; Pricop L;
    Arthritis Res Ther; 2018 Mar; 20(1):47. PubMed ID: 29544534
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Efficacy and safety of intravenous secukinumab in noninfectious uveitis requiring steroid-sparing immunosuppressive therapy.
    Letko E; Yeh S; Foster CS; Pleyer U; Brigell M; Grosskreutz CL;
    Ophthalmology; 2015 May; 122(5):939-48. PubMed ID: 25638011
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial.
    van der Heijde D; Baraliakos X; Sieper J; Deodhar A; Inman RD; Kameda H; Zeng X; Sui Y; Bu X; Pangan AL; Wung P; Song IH
    Ann Rheum Dis; 2022 Nov; 81(11):1515-1523. PubMed ID: 35788492
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Sustained efficacy, safety and patient-reported outcomes of certolizumab pegol in axial spondyloarthritis: 4-year outcomes from RAPID-axSpA.
    van der Heijde D; Dougados M; Landewé R; Sieper J; Maksymowych WP; Rudwaleit M; Van den Bosch F; Braun J; Mease PJ; Kivitz AJ; Walsh J; Davies O; Bauer L; Hoepken B; Peterson L; Deodhar A
    Rheumatology (Oxford); 2017 Sep; 56(9):1498-1509. PubMed ID: 28498975
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy and safety of IL-17 inhibitors for the treatment of ankylosing spondylitis: a systematic review and meta-analysis.
    Yin Y; Wang M; Liu M; Zhou E; Ren T; Chang X; He M; Zeng K; Guo Y; Wu J
    Arthritis Res Ther; 2020 May; 22(1):111. PubMed ID: 32398096
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial.
    van der Heijde D; Schiff MH; Sieper J; Kivitz AJ; Wong RL; Kupper H; Dijkmans BA; Mease PJ; Davis JC;
    Ann Rheum Dis; 2009 Jun; 68(6):922-9. PubMed ID: 18701556
    [TBL] [Abstract][Full Text] [Related]  

  • 60. One-year efficacy and safety results of secukinumab in patients with rheumatoid arthritis: phase II, dose-finding, double-blind, randomized, placebo-controlled study.
    Genovese MC; Durez P; Richards HB; Supronik J; Dokoupilova E; Aelion JA; Lee SH; Codding CE; Kellner H; Ikawa T; Hugot S; Ligozio G; Mpofu S
    J Rheumatol; 2014 Mar; 41(3):414-21. PubMed ID: 24429175
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 39.